All articles

Tesamorelin: visceral fat, the liver and what the studies showed

What this drug is and what studies showed about it

What it is

Tesamorelin is a copy of the hormone that "asks" the pituitary to get to work.

  • a hypothalamic hormone, and the drug is its exact copy
  • it prompts the pituitary to release its own growth hormone
  • the drug is given as an injection under the skin

How it works

The drug does not replace the hormone, it starts its production.

  • the pituitary receives the signal
  • it releases the hormone in pulses by itself
  • the body keeps its own rhythm

What it was made for

The main target is the fat around the organs in the abdomen.

  • in HIV, fat sometimes collects in the abdomen
  • the drug is approved exactly for this
  • it has one precise task

Which fat goes

The fat inside the abdomen goes, not the fat under the skin.

  • the fat around the organs decreases
  • the fat under the skin barely changes
  • the waist gets a little smaller

It is not for weight loss

The weight on the scale stays almost the same.

  • the drug changes body composition
  • lean mass grows a little
  • so the number on the scale stands still

The liver

The drug is also studied for fat in the liver.

  • in people with HIV there was less fat in the liver
  • the results are encouraging
  • there is no official indication for this

People without HIV

It has been studied in people without HIV too.

  • in adults with reduced growth hormone there was less abdominal fat
  • in people with diabetes blood sugar did not get worse
  • such studies are small

Memory and attention

For memory the picture is mixed.

  • in older adults planning and attention got better
  • in people with HIV no difference was found
  • this is still a research topic

What happens after stopping

While the drug is given, the effect lasts.

  • after stopping, the abdominal fat comes back
  • the effect lasts only while treatment goes on
  • the doctor decides the duration

What needs to be checked

Regular tests are needed during treatment.

  • the blood sugar level
  • the level of the growth factor IGF-1
  • swelling and joint pain are possible

Who should see a doctor first

There are cases where it cannot be done without a doctor.

  • pituitary diseases and pituitary surgery
  • a tumor now or in the past
  • pregnancy and breastfeeding
  • allergy to the components

Important. Only a doctor prescribes such a drug, after an examination and tests.

The main point

A drug with a precise target: the fat around the organs.

  • it works on visceral fat, not on weight
  • it lasts while treatment goes on
  • a doctor decides, not self-treatment

Frequently asked questions

It is a synthetic analogue of human growth hormone-releasing hormone, 44 amino acids long with a protective hexenoyl group. It makes the pituitary gland release its own growth hormone. It has been approved in the US since 2010 (FDA label EGRIFTA WR, rev. 03/2025).

No, the FDA label states the drug is not indicated for weight loss. Over 26 weeks weight changed by −0.4 and +0.2 kg vs placebo, a non-significant difference; visceral fat goes down, subcutaneous fat does not change (806 people, 2 studies; Falutz J J Clin Endocrinol Metab 2010. PMID 20554713).

Visceral fat returns: over 26 weeks on placebo after treatment it rose by 22% in the first study and 16% in the second (FDA label, Table 4). IGF-1 returns to baseline within 10 weeks (152 people, 1 study; Baker LD Arch Neurol 2012. PMID 22869065).

In people with HIV, the liver fat fraction fell by 4.1 percentage points vs placebo (−37%) over 12 months, and fibrosis progressed less often: 2 people vs 9 on placebo; existing fibrosis did not decrease (61 people, 1 study; Stanley TL Lancet HIV 2019. PMID 31611038). This use is not covered by the label.

On average blood sugar changed non-significantly, but HbA1c 6.5% and above at week 26 was seen in 5% vs 1% on placebo; IGF-1 above 3 standard deviations in 36% (806 people, 2 studies; FDA label). Glucose and IGF-1 are checked before and during treatment.

There is no fixed duration. The dose is injected under the skin of the abdomen once a day: 1.28 mg for Egrifta WR or 1.4 mg for Egrifta SV; the studies used 2 mg. The doctor reviews the need to continue based on the reduction in visceral fat (FDA label).

In people aged 55–87 without HIV the overall cognitive score improved (P = 0.03), executive function P = 0.005, verbal memory P = 0.08 (152 people, 1 study, 20 weeks; Baker LD Arch Neurol 2012. PMID 22869065). In people with HIV the difference between groups was P = 0.673 (73 people, 1 study; Ellis RJ J Infect Dis 2025. PMID 39813152).

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question